OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
-15.93%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$307M
AUM Growth
+$307M
(-26%)
Cap. Flow
-$40.3M
Cap. Flow
% of AUM
-13.12%
Top 10 Holdings %
Top 10 Hldgs %
66.99%
Holding
55
New
8
Increased
13
Reduced
15
Closed
15
Top Buys
| 1 |
TG Therapeutics
TGTX
|
$15.8M |
| 2 |
Catalyst Pharmaceutical
CPRX
|
$14.1M |
| 3 |
Biodesix
BDSX
|
$3.04M |
| 4 |
Applied Therapeutics
APLT
|
$2.22M |
| 5 |
Ocular Therapeutix
OCUL
|
$2.16M |
Top Sells
| 1 |
Crinetics Pharmaceuticals
CRNX
|
$14.1M |
| 2 |
TELA Bio
TELA
|
$6.64M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$6.21M |
| 4 |
Theravance Biopharma
TBPH
|
$5.63M |
| 5 |
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
|
$5.57M |
Sector Composition
| 1 | Healthcare | 97.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Harrow
HROW
$1.44B
| $54.5M | 17.74% | 3,795,000 +20,000 | +0.5% | +$287K |
|
|
SLRN
2
DELISTED
ACELYRIN
SLRN
| $42.2M | 13.72% | 4,146,138 -12,500 | -0.3% | -$127K |
|
|
3
Ocular Therapeutix
OCUL
$2.12B
| $20.3M | 6.61% | 6,468,000 +688,000 | +12% | +$2.16M |
|
|
4
TG Therapeutics
TGTX
$4.65B
| $15.8M | 5.14% | +1,890,000 | New | +$15.8M |
|
5
Rhythm Pharmaceuticals
RYTM
$6.85B
| $15M | 4.87% | 653,000 -82,000 | -11% | -$1.88M |
|
|
6
Catalyst Pharmaceutical
CPRX
$2.52B
| $14.1M | 4.58% | +1,205,000 | New | +$14.1M |
|
7
Keros Therapeutics
KROS
$618M
| $11.5M | 3.74% | 360,400 +7,750 | +2% | +$247K |
|
8
Biohaven
BHVN
$1.63B
| $11.4M | 3.71% | 439,000 -101,000 | -19% | -$2.63M |
|
|
9
Crinetics Pharmaceuticals
CRNX
$2.92B
| $11M | 3.58% | 370,000 -475,000 | -56% | -$14.1M |
|
10
Eton Pharmaceutcials
ETON
$464M
| $10.1M | 3.3% | 2,430,270 +145,270 | +6% | +$606K |
|
11
IDEAYA Biosciences
IDYA
$2.15B
| $8.4M | 2.73% | 311,500 -103,500 | -25% | -$2.79M |
|
|
MOR
12
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $8.13M | 2.64% | 1,209,380 | – | – |
|
|
13
TELA Bio
TELA
$70.5M
| $6M | 1.95% | 750,000 -830,000 | -53% | -$6.64M |
|
14
Edgewise Therapeutics
EWTX
$1.51B
| $5.02M | 1.63% | 875,405 +60,405 | +7% | +$346K |
|
15
KalVista Pharmaceuticals
KALV
$678M
| $4.82M | 1.57% | 500,000 -220,000 | -31% | -$2.12M |
|
|
MRNS
16
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $4.7M | 1.53% | 584,000 -41,000 | -7% | -$330K |
|
17
Vaxcyte
PCVX
$4B
| $4.59M | 1.49% | 90,000 -87,000 | -49% | -$4.44M |
|
18
Protara Therapeutics
TARA
$120M
| $4.5M | 1.46% | 2,692,594 | – | – |
|
19
UroGen Pharma
URGN
$900M
| $4.48M | 1.46% | 320,000 -250,000 | -44% | -$3.5M |
|
20
Geron
GERN
$893M
| $4.06M | 1.32% | 1,915,000 -435,000 | -19% | -$922K |
|
21
Gossamer Bio
GOSS
$562M
| $3.96M | 1.29% | 4,754,200 +1,384,200 | +41% | +$1.15M |
|
22
4D Molecular Therapeutics
FDMT
$288M
| $3.93M | 1.28% | 308,500 +86,800 | +39% | +$1.1M |
|
23
Xoma
XOMA
$392M
| $3.87M | 1.26% | 274,500 -500 | -0.2% | -$7.05K |
|
24
Trevi Therapeutics
TRVI
$883M
| $3.72M | 1.21% | 1,705,900 +4,400 | +0.3% | +$9.59K |
|
25
Liquidia Corp
LQDA
$2.38B
| $3.62M | 1.18% | 570,700 | – | – |
|